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Introduction {#cam41173-sec-0001}
============

Bone‐targeted agents, such as bisphosphonates or denosumab, are used in patients with bone malignancy to prevent symptomatic skeletal events: pathological fractures, spinal cord compression, or need for radiation or surgery to bone [1](#cam41173-bib-0001){ref-type="ref"}, [2](#cam41173-bib-0002){ref-type="ref"}. The bone malignancies include multiple myeloma and bone metastases from solid tumors, primarily of prostate, breast, or lung [1](#cam41173-bib-0001){ref-type="ref"}. Preventing symptomatic skeletal events improves quality of life. In multiple myeloma and in the adjuvant setting of breast cancer, bone‐targeted therapy may also delay disease progression and prolong survival [3](#cam41173-bib-0003){ref-type="ref"}, [4](#cam41173-bib-0004){ref-type="ref"}, [5](#cam41173-bib-0005){ref-type="ref"}, [6](#cam41173-bib-0006){ref-type="ref"}.

Osteonecrosis of the jaw (ONJ), first described in 2003 after intravenous bisphosphonate use [7](#cam41173-bib-0007){ref-type="ref"}, is a potentially severe adverse effect of bone‐targeted therapy [8](#cam41173-bib-0008){ref-type="ref"}. Among currently or previously treated patients, ONJ is diagnosed in the presence of exposed bone or bone that can be probed through a fistula in the maxillofacial region [8](#cam41173-bib-0008){ref-type="ref"}. The lesion must persist for at least 8 weeks in the absence of signs of malignancy or history of radiotherapy to the jaws [8](#cam41173-bib-0008){ref-type="ref"}. In clinical trials, up to 5% of cancer patients develop ONJ as late as 3 years of bone‐targeted therapy [9](#cam41173-bib-0009){ref-type="ref"}, [10](#cam41173-bib-0010){ref-type="ref"}, [11](#cam41173-bib-0011){ref-type="ref"}, [12](#cam41173-bib-0012){ref-type="ref"}, [13](#cam41173-bib-0013){ref-type="ref"}, [14](#cam41173-bib-0014){ref-type="ref"}. Treatment of ONJ may involve discontinuation of bone‐targeted agents [15](#cam41173-bib-0015){ref-type="ref"}, [16](#cam41173-bib-0016){ref-type="ref"}, [17](#cam41173-bib-0017){ref-type="ref"}, despite their therapeutic benefits [11](#cam41173-bib-0011){ref-type="ref"}, [14](#cam41173-bib-0014){ref-type="ref"}.

Data on survival following ONJ among cancer patients will help contribute to the understanding of risk--benefit trade‐offs associated with bone‐targeted therapy for cancer. Previously, survival following ONJ was studied in a cohort of 21 renal cell carcinoma patients treated with zoledronic acid, whereby patients developing ONJ (*N* = 6) had a 17‐month longer median survival compared with patients not developing ONJ [15](#cam41173-bib-0015){ref-type="ref"}. Since follow‐up started at cancer diagnosis, which may precede ONJ by years, the observed association could be likely a result of immortal time bias [18](#cam41173-bib-0018){ref-type="ref"}.

We conducted a nationwide cohort study in Denmark to examine the association between ONJ and survival among cancer patients treated with bone‐targeted agents.

Materials and Methods {#cam41173-sec-0002}
=====================

Setting {#cam41173-sec-0003}
-------

Denmark provides tax‐funded health care to all its residents, and Danish registries and databases contain extensive individual‐level health care data, including data on cancer therapies from 1999 [19](#cam41173-bib-0019){ref-type="ref"}. Individual‐level data from all data sources are linkable, enabling virtually complete follow‐up [20](#cam41173-bib-0020){ref-type="ref"}.

Cancer population {#cam41173-sec-0004}
-----------------

The study eligibility period started on 15 October 2010, the date when the first ONJ case in a cancer patient was recorded in the Danish ONJ database (described below). We used the Danish Cancer Registry (DCR) and the Danish National Patient Registry (DNPR) to identify all cancer patients who were alive and residing in Denmark between 15 October 2010 and 31 December 2015. The DCR has recorded all incident cancers in Denmark since 1943 [21](#cam41173-bib-0021){ref-type="ref"} and is virtually complete [22](#cam41173-bib-0022){ref-type="ref"}. Recorded data include diagnosis date, cancer site and stage at diagnosis. Since the DCR was updated until 2013 at the time of this study, we used the DNPR to identify cancer patients diagnosed in 2014--2015. The completeness of the DNPR compared with the DCR is 87--96% [23](#cam41173-bib-0023){ref-type="ref"}, [24](#cam41173-bib-0024){ref-type="ref"}. The DNPR contains information on all hospitalizations since 1977 and on all outpatient clinic visits since 1995. Diagnoses were registered using the *International Classification of Diseases*,*Eighth Revision* (ICD‐8) through 1993 and the ICD‐10 thereafter. In Denmark, cancer treatments, including denosumab and intravenous bisphosphonates, are administered in hospitals. Intravenous bisphosphonates were introduced to the Danish hospital sector in 1997, 2 years after their approval in the European Union for multiple myeloma and 1 year after their approval for prevention of skeletal events following bone metastasis. Denosumab was introduced for skeletal events prevention in 2011 [25](#cam41173-bib-0025){ref-type="ref"}.

The ONJ cohort {#cam41173-sec-0005}
--------------

The ONJ cohort consisted of patients from the cancer population with incident clinically confirmed ONJ, as recorded in the Danish ONJ database. This research database was established to register ONJ events nationwide [26](#cam41173-bib-0026){ref-type="ref"}. In Denmark, all patients with suspected ONJ are referred to hospital‐based departments of oral and maxillofacial surgery [26](#cam41173-bib-0026){ref-type="ref"}. Specialists in these departments (physicians, dentists, or oral surgeons) report the confirmed ONJ diagnoses to the Danish ONJ database. The database was established in October 2011; confirmed ONJs diagnosed between October 2010 and September 2011 were registered retrospectively using information from medical records.

The comparison cohort {#cam41173-sec-0006}
---------------------

We used the DNPR and the Danish ONJ database to construct a comparison cohort of cancer patients without ONJ and with a record of hospital‐administered treatment with bisphosphonates or denosumab. Cancer patients receiving treatment exclusively for osteoporosis have a lower ONJ risk [27](#cam41173-bib-0027){ref-type="ref"} and presumably a better prognosis. Therefore, we selected only treatment records initiating from cancer diagnosis date and before the date of confirmed ONJ diagnosis (defined as the index date). For each ONJ patient, we randomly sampled up to 10 patients from the treated cancer population who were alive and without ONJ on the index date, matched on birth year (within 3 years), cancer site, year of cancer diagnosis, and distant stage at cancer diagnosis. Patients with records of diagnostic codes indicative of ONJ in the DNPR before the index date were not eligible to enter the comparison cohort [28](#cam41173-bib-0028){ref-type="ref"}.

Covariates {#cam41173-sec-0007}
----------

From the DNPR, we obtained information on recorded diagnoses of distant metastases at the index date, and on the comorbidity level, since 1977, expressed using the Charlson Comorbidity Index score (excluding cancer), as 0, 1--2, or 3+ [29](#cam41173-bib-0029){ref-type="ref"}, [30](#cam41173-bib-0030){ref-type="ref"}.

Table [S1](#cam41173-sup-0001){ref-type="supplementary-material"} lists definitions of the study variables.

Statistical analysis {#cam41173-sec-0008}
--------------------

Patients were followed from the index date until the earliest of death, emigration, or 15 June 2016. We used the Kaplan--Meier estimator to compute and display survival both for the ONJ patients and the comparison cohort. Furthermore, we constructed adjusted survival curves using stabilized weights that represented each patient\'s inverse probability of having ONJ. Briefly, these weights were estimated in a logistic regression model with ONJ as the dependent variable, and sex, distant metastasis, and comorbidity level on the index date as the independent variables [31](#cam41173-bib-0031){ref-type="ref"}. We used stratified Cox regression to compute hazard ratios as estimates of mortality rate ratios (MRRs) and the associated 95% confidence intervals (CIs) adjusted for sex, and for the presence of distant metastasis, and the level of other comorbidity on the index date. The proportionality assumption was examined using Kolmogorov‐type supremum tests [32](#cam41173-bib-0032){ref-type="ref"}.

To assess the impact of potential incomplete registration of ONJ before 2012, we performed a sensitivity analysis restricted to patients enrolled between 2012 and 2015. Finally, we performed an additional sensitivity analysis restricted to patients without a diagnosis of osteoporosis. Analyses were conducted using SAS software version 9.4 (SAS Inc., Cary, NC). The study was approved by the Danish Data Protection Agency (record number 2012‐41‐0045). Patient consent is not required by Danish law for studies based on routine electronic data.

Results {#cam41173-sec-0009}
=======

During the study period, we identified 184 patients for inclusion in the ONJ cohort and 1067 patients for inclusion in the comparison cohort (Table [1](#cam41173-tbl-0001){ref-type="table-wrap"}). Eighty‐nine percent of patients had breast cancer or prostate cancer. Median age at index date was 68 years (interquartile range \[IQR\]: 63--74 years). Median time from cancer diagnosis to confirmed ONJ was 6.3 years (IQR: 2.9--11 years). Thirty‐five patients in the ONJ cohort (80% of whom had cancers at sites other than breast and prostate) could not be matched to anyone with a history of bone‐targeted therapy, resulting in a matched ONJ cohort of 149 patients (Table [1](#cam41173-tbl-0001){ref-type="table-wrap"}). The median time from first‐recorded therapy to the index date was 2.1 years (IQR: 1.2--3.6 years) in the matched ONJ cohort, and 1.4 years in the comparison cohort (IQR: 0.6--2.9 years).

###### 

Characteristics of the osteonecrosis of the jaw (ONJ) cohort and the comparison cohort

  Characteristics                                                           ONJ cohort (*N* = 184)   Matched ONJ cohort (*N* = 149)   Comparison cohort (*N* = 1067)                 
  ------------------------------------------------------------------------- ------------------------ -------------------------------- -------------------------------- ------ ------ ------
  Age on the index date (years)                                                                                                                                                      
  36--54                                                                    18                       9.78                             14                               9.40   69     6.47
  55--64                                                                    44                       23.9                             38                               25.5   261    24.5
  65--79                                                                    97                       52.7                             82                               55.0   679    63.6
  80--94                                                                    25                       13.6                             15                               10.1   58     5.44
  Sex                                                                                                                                                                                
  Female                                                                    115                      62.5                             96                               64.4   687    64.4
  Index year                                                                                                                                                                         
  2010--2011                                                                9                        4.89                             6                                4.03   30     2.81
  2012--2015                                                                175                      95.1                             143                              96.0   1037   97.2
  Year of cancer diagnosis                                                                                                                                                           
  1980--1994                                                                17                       9.24                             10                               6.71   72     6.75
  1995--1999                                                                14                       7.61                             12                               8.05   93     8.72
  2000--2003                                                                22                       12.0                             16                               10.7   129    12.1
  2004--2013                                                                124                      67.4                             105                              70.5   728    68.2
  2014--2015                                                                7                        3.80                             6                                4.03   45     4.22
  Cancer site                                                                                                                                                                        
  Breast                                                                    89                       48.4                             84                               56.4   645    60.4
  Prostate                                                                  46                       25.0                             44                               29.5   331    31.0
  Kidney                                                                    15                       8.15                             4                                2.68   4      0.37
  Multiple myeloma                                                          9                        4.89                             8                                5.37   62     5.81
  Lung                                                                      8                        4.35                             6                                4.03   20     1.87
  Other cancer sites                                                        17                       9.24                             3                                2.01   5      0.47
  Cancer stage at diagnosis                                                                                                                                                          
  Local or regional                                                         98                       53.3                             81                               54.4   670    62.8
  Distant metastasis                                                        47                       25.5                             38                               25.5   200    18.7
  Unknown stage                                                             27                       14.7                             22                               14.8   135    12.7
  N/A (nonsolid tumors)                                                     12                       6.52                             8                                5.37   62     5.81
  Distant metastasis on the index date                                      111                      60.3                             91                               61.1   470    44.1
  Years from cancer diagnosis to the index date*,* median (IQR)             6.3 (2.9--11)            6.1 (2.9--9.9)                   6.6 (3.2--10)                                  
  History of hospital‐based therapy with bone‐targeted agents               158                      85.9                             141                              94.6   1067   100
  History of osteoporosis                                                   25                       13.6                             14                               9.40   186    17.4
  Charlson Comorbidity Index score[a](#cam41173-note-0003){ref-type="fn"}                                                                                                            
  0                                                                         99                       53.8                             87                               58.4   706    66.2
  1--2                                                                      69                       37.5                             48                               32.2   295    27.7
  3+                                                                        16                       8.70                             14                               9.40   66     6.19

Other cancer sites included other primary and secondary cancers. IQR, interquartile range; *N*, number of individuals; Comparison cohort, cohort within the cancer population without ONJ and with a recorded history of hospital‐based therapy with bone‐targeted agents starting from cancer diagnosis date; N/A, nonapplicable.

Excluding cancer.
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During median follow‐up of 1.4 years (IQR: 0.7--2.3 years) in the ONJ cohort, 1‐year survival was 70% (95% CI: 63%--76%) and 3‐year survival was 42% (95% CI: 34%--51%). One‐year survival in the ONJ cohort was 77% (95% CI: 67%--85%) among breast cancer patients and 66% (95% CI: 50%--78%) among prostate cancer patients. Three‐year survival was 47% (95% CI: 35%--58%) among breast cancer patients with ONJ and 29% (95% CI: 13%--47%) among prostate cancer patients with ONJ. The comparison cohort had a median follow‐up of 1.8 years (IQR: 0.9--2.6 years), and the 1‐ and 3‐year survival estimates were 80% (95% CI: 77%--82%) and 54% (95% CI: 50%--58%), respectively (Fig. [1](#cam41173-fig-0001){ref-type="fig"}A).

![Overall survival and corresponding 95% CIs (shaded areas) in the osteonecrosis of the jaw (ONJ,*N* = 149) and in the matched comparison cohort (*N* = 1067). (A) Unadjusted survival curves and (B) adjusted survival curves using inverse probability weights. The ONJ confirmation date served as the index date for the ONJ cohort and matched members of the comparison cohort.](CAM4-6-2271-g001){#cam41173-fig-0001}

Among the matched patients, ONJ was associated with an adjusted MRR of 1.31 (95% CI: 1.01--1.71) (Table [2](#cam41173-tbl-0002){ref-type="table-wrap"} and Fig. [1](#cam41173-fig-0001){ref-type="fig"}B). The estimated median survival time was 2.1 years in the ONJ cohort and 3.4 years in the matched comparison cohort. Although imprecisely measured, the MRR was higher for prostate cancer than for breast cancer patients (Table [2](#cam41173-tbl-0002){ref-type="table-wrap"}). The sensitivity analyses restricted to the 2012--2015 eligibility period or to cancer patients without a diagnosis of osteoporosis produced consistent results compared with the main analysis (Table [S2](#cam41173-sup-0001){ref-type="supplementary-material"}).

###### 

All‐cause mortality rates and mortality rate ratios (MRRs) in cancer patients with osteonecrosis of the jaw (ONJ), relative to the comparison cohort

  Cancer site   Cohort   *N*   *N* deaths   Person‐years   All‐cause mortality                                                                                                           
  ------------- -------- ----- ------------ -------------- --------------------- ------------ ----------------------------------------- ----------------------------------------- ------ ------------
  All           ONJ      149   80           253            31.6                  25.0--39.3   1.48                                      1.14--1.92                                1.31   1.01--1.71
  Comparison    1067     417   1994         20.9           19.0--23.0            Reference    ---                                       Reference                                 ---    
  Breast        ONJ      84    42           165            25.5                  18.4--34.5   1.34                                      0.95--1.90                                1.13   0.80--1.60
  Comparison    645      250   1276         19.6           17.2--22.2            Reference    ---                                       Reference                                 ---    
  Prostate      ONJ      44    26           60             43.4                  28.4--63.6   1.72                                      1.08--2.74                                1.60   0.99--2.58
  Comparison    331      127   540          23.5           19.6--28.0            Reference    ---                                       Reference                                 ---    
  Other         ONJ      21    12           29             41.7                  21.5--72.8   [c](#cam41173-note-0007){ref-type="fn"}   [c](#cam41173-note-0007){ref-type="fn"}          
  Comparison    91       40    178          22.4           16.0--30.5                                                                                                                    

Stratified analyses by cancer site are provided according to: breast cancer, prostate cancer and other cancer sites. *N*, number of individuals; Comparison cohort, comparison cohort from the cancer population without ONJ and with a record of bone‐targeted therapy initiating from cancer diagnosis date.

Per 100 person‐years.

Adjusted for record of distant metastasis (yes/no) registered on/before the index date, level of other comorbidity, and for sex (except in analyses for prostate cancer and for breast cancer).

Proportionality assumption was not fulfilled, as verified using Kolmogorov‐type supremum tests (unadjusted model, *P* = 0.014; adjusted model, *P* = 0.010).
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Discussion {#cam41173-sec-0010}
==========

In this cohort study of cancer patients treated with bone‐targeted agents, 1‐year survival after incident ONJ was 70%. Less than half of the ONJ‐affected patients survived for 3 years. After adjustment for measured prognostic factors, ONJ was associated with a mortality rate ratio of 1.31 compared with patients without ONJ. This finding contradicts the previously reported prolonged survival associated with ONJ [15](#cam41173-bib-0015){ref-type="ref"}.

We report results from the largest nationwide cohort of cancer patients to date with clinically confirmed ONJ, with complete follow‐up for death and migrations. Although ascertainment of ONJ was potentially incomplete before 2012, our results did not materially change after restriction to a period with more complete ONJ ascertainment. Among cancer patients, the positive predictive value of a DNPR‐recorded hospital administration of intravenous bisphosphonate is 98% [33](#cam41173-bib-0033){ref-type="ref"}. However, the indication for bone‐targeted therapies is not recorded in the DNPR. Although the prevalence of osteoporosis was higher in the comparison cohort (17%) than in the ONJ cohort (9%), excluding patients with osteoporosis did not affect our MRRs. A smaller proportion of cancer patients without osteoporosis could nevertheless have received bone‐targeted agents to prevent cancer treatment‐induced bone loss [1](#cam41173-bib-0001){ref-type="ref"}, [34](#cam41173-bib-0034){ref-type="ref"}. It is not known whether cancer therapy‐induced bone loss affects survival aside from its associated cancer stage. Therefore, we have not considered it as a potential confounder in our study.

The association of ONJ with mortality remaining after adjustment for measured prognostic factors may be due to ONJ being a marker of underlying advanced disease, or of behaviors associated with survival, such as smoking [35](#cam41173-bib-0035){ref-type="ref"}, [36](#cam41173-bib-0036){ref-type="ref"}. Missing data on cancer stage at diagnosis was observed in nearly 13--15% of the cohorts. Subsequently, missing registration on distant cancer stage is expected to be higher during the median period of 6 years from cancer diagnosis until the index date. Nonetheless, assuming most cancer patients received bone‐targeted therapy for bone malignancy [33](#cam41173-bib-0033){ref-type="ref"}, [34](#cam41173-bib-0034){ref-type="ref"}, and that time elapsed from first therapy record to the index date was longer in the ONJ than in the comparison cohort, ONJ patients could have more advanced bone disease at start follow‐up than members of the comparison cohort.

In conclusion, ONJ was associated with reduced survival among cancer patients treated with bone‐targeted agents. ONJ may be a marker of advanced disease or of survival‐related lifestyle characteristics.
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**Table S1.** Definitions of study variables by their specific ICD and procedure codes.

**Table S2.** Sensitivity analyses of the association between ONJ and mortality among cancer patients treated with bone‐targeted agents, restricting the study eligibility period to 2012--2015, or to patients without osteoporosis.

###### 

Click here for additional data file.
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